The biopharma tools developer secured $25m in a Novo-led series A round in February last year.
Unchained Labs, a life sciences tool startup backed by pharmaceutical company Novo, has raised $25m in series B funding, according to a securities filing on Wednesday.
Founded in 2015, Unchained has developed a range of tools for biologics research, including a biologics stability screener, an aggregation predictor and a protein sizing system.
Unchained previously raised $25m in a February 2015 series A round led by Novo Ventures, a corporate venturing subsidiary of Novo. The round also featured venture capital…
